While biosimilars have gained traction in markets such as Europe and the United States, Canada’s progress has been cautious and comparatively slow. Despite the strong potential for cost savings and access expansion, a mix of regulatory, market, and policy challenges has hindered the domestic biosimilars market. The question is: why, and what can be done to change the trajectory?

 

1. A Fragmented Policy Environment

One of the biggest barriers is Canada’s decentralized healthcare system, where drug funding and policy decisions are made at the provincial level. This has led to uneven uptake of biosimilars across the country. For example, while British Columbia and Alberta introduced mandatory switching policies for some biologics, other provinces delayed or lacked clear biosimilar strategies altogether.

This lack of national alignment has created market uncertainty, slowed manufacturer investment, and made it difficult to implement wide-scale switching programs.

 

2. Market Size and Economics

Canada’s smaller population—coupled with high regulatory standards—has made the biosimilar business case less compelling for some global manufacturers. Compared to the U.S. or EU, the Canadian market may be seen as a lower priority for launch, especially given the cost of building regulatory submissions that meet Health Canada’s requirements.

Additionally, reference biologics in Canada are often already heavily discounted through negotiations with public payers (e.g. via pCPA), limiting the price advantage biosimilars can offer. This shrinks the commercial incentive for companies to enter the market.

 

3. Physician and Patient Reluctance

While safety and efficacy concerns have largely been addressed in the science, perception lags behind reality. Many physicians, especially in specialized fields, have been cautious in adopting biosimilars—particularly when it comes to non-medical switching.

Patients, too, may push back on switching, especially if they have responded well to an originator product. Without clear, coordinated education campaigns, misinformation or uncertainty can slow biosimilar adoption.

4. Regulatory Bottlenecks and Evolving Guidance

Health Canada is generally seen as a rigorous but responsive regulator, yet companies still face challenges navigating requirements that differ from those of the FDA or EMA. For biosimilars, this includes:

• Clinical comparability requirements
• Varying expectations around interchangeability
• Navigating revised guidance (e.g., CTD structure, post-NOC changes)

Delays or uncertainty around guidance implementation can increase time to market, especially for smaller biotechs or new entrants.

 

What Can Be Done?

✓ Create National Consistency: A coordinated national strategy—similar to the EU’s approach—would provide clarity and confidence to manufacturers, physicians, and patients. National biosimilar switching policies could help streamline uptake and normalize biosimilar use.

✓ Build Domestic Capacity: Investing in domestic biomanufacturing infrastructure and encouraging public-private partnerships can help Canada produce biosimilars locally. Initiatives like the Biomanufacturing and Life Sciences Strategy are steps in the right direction—but targeted support is needed for biosimilars specifically.

✓ Educate the Market: Health Canada, industry, and professional associations can collaborate on joint education campaigns that clarify biosimilar safety, efficacy, and cost advantages. Peer-led programs and patient advocacy engagement can build trust and confidence.

✓ Streamline Regulatory Alignment: Continued participation in global harmonization efforts (like ICH M4Q and WHO guidance) will help reduce duplicative requirements and make it easier for companies to submit in multiple jurisdictions, including Canada.

The Bottom Line

Canada has strong regulatory science, a trusted healthcare system, and a growing innovation ecosystem. What’s missing is strategic coordination, scaled infrastructure, and market confidence. With the right partnerships and investments, Canada can position itself not only as a biosimilar-friendly market—but as a global leader in the future of affordable biologics.

 

📍 Want to learn more?

Join us at the Biologics & Biosimilars Conference in Montreal, August 19th, where Health Canada leaders and industry experts will unpack these challenges and explore new pathways forward.

🔗 Learn more & register